Abstract:

Objective To investigate the effects of radioactive iodine (¹³¹I) therapy for differentiated thyroid carcinoma (DTC) on liver and renal function. Methods The clinical data of 106 patients with DTC were collected, and patients were divided into low dose group (≤1.85 GBq, n=19), middle dose group (2.22 GBq and 2.96 GBq, n=50) and high dose group (≥3.7 GBq, n=37) according to ¹³¹I doses. The results of liver and renal examinations were compared and analysed before and after ¹³¹I therapy among groups. Results The data of liver function were complete in 67 patients before and after ¹³¹I therapy (low dose group, n=18; middle dose group, n=37; high dose group, n=12). Compared with those before treatment, the total aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were higher (P<0.05), while the AST and ALT levels of the majority (82.1%) were in the normal ranges. The data of renal function were complete in all the 106 patients before and after ¹³¹I therapy. There was no significant difference in blood urea nitrogen (BUN), serum creatinine (SCr) and uric acid (UA) before and after treatment in each group (P>0.05). Conclusion ¹³¹I therapy is safe for DTC, with no significant effect on liver and renal function.

Key words: radioactive iodine, differentiated thyroid carcinoma, liver function, renal function